Harrow earnings release, May 11, 2026
Harrow
Announces First Quarter 2026 Financial Results
First
Quarter 2026 and Selected Highlights:
NASHVILLE,
Tenn., May 11, 2026 – Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the first quarter ended March 31, 2026. The Company also posted its first-quarter Letter to Stockholders and corporate presentation to the “Investors” section of its website at harrow.com. The Company encourages Harrow stockholders to review these documents, which provide additional details concerning the historical results and future expectations for the business.
“The demand for Harrow’s key products has never been stronger, and our visibility into our demand trajectory – across our portfolio – keeps us entirely on track to reach our forecasted financial goals for the year,” said Mark
L. Baum, Chief Executive Officer of Harrow. “Although our first-quarter reported revenue reflects an estimated $8 million gross-to-net reduction associated with our new commercial coverage for VEVYE, this adjustment does not reflect the profitable, recurring, and significant patient base established during the quarter. Harrow is now positioned to realize the full financial benefits of this coverage relationship beginning in Q2 2026.”
Baum continued, “Prior to the quarter, we established business rules with specific assumptions regarding these new
VEVYE commercial patients. As the period unfolded, the surge in demand among patients with high-deductible plans significantly outpaced our initial models. This created temporary gross-to-net pressure, which was resolved through business rules adjustments. With these rules now in place, we are now positioned to realize the expected financial benefit of our expanded commercial access, and we are already seeing highly encouraging net pricing indicators early in the second quarter.”
“Our core commercial engine is accelerating. VEVYE delivered record prescription performance and has officially surpassed XIIDRA on a monthly total prescription basis. Across our key growth drivers - VEVYE, IHEEZO, and TRIESENCE - we are seeing robust prescriber adoption, expanding market share, and durable momentum. With our expanded commercial organization now fully deployed, we remain highly confident in our ability to deliver on our 2026 revenue guidance of $350 million to $365 million.”
Key
First Quarter Demand Indicators
:
VEVYE:
IHEEZO:
TRIESENCE:
First
Quarter 2026 Financial Results:
Conference
Call and Webcast
Harrow will host a conference call to discuss the results at 8:00 a.m. ET on Tuesday, May 12, 2026. Participants can access the live webcast of Harrow’s presentation on the “Investors” page of Harrow’s website. A replay of the webcast will be available on the Company’s website for one year.
To participate via telephone, please register in advance using this link. Upon registration, all telephone participants will receive a confirmation email with detailed instructions, including a unique dial-in number and PIN, to access the call.
About
Harrow
Harrow,
Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma, and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on
LinkedIn.
Forward-Looking
Statements
Financial statements
Income Statement
For the Three Months Ended March 31, — Additional product-related revenue figures are reflected in the table below:
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | For the Three Months Ended March 31, – 2025 | |
|---|---|---|---|---|
| IHEEZO | 1,851,000 | 4.0% | 5,222,000 | 11.0% |
| VEVYE | 20,947,000 | 47.0% | 21,516,000 | 45.0% |
| Other branded products | 7,833,000 | 18.0% | 956,000 | 2.0% |
| Other revenues | 73,000 | 0.0% | 86,000 | 0.0% |
| Branded revenue, net | 30,704,000 | 69.0% | 27,780,000 | 58.0% |
| ImprimisRx revenue, net | 13,499,000 | 31.0% | 20,051,000 | 42.0% |
| Total revenues, net | 44,203,000 | 100.0% | 47,831,000 | 100.0% |
Income Statement
For the Three Months Ended March 31, — Selected financial highlights regarding GAAP operating results for the three months ended March 31, 2026 and 2025 are as follows:
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Total revenues | 44,203,000 | 47,831,000 | |
| Cost of sales | -17,158,000 | -15,524,000 | |
| Gross profit | 27,045,000 | 32,307,000 | |
| Selling, general and administrative | 43,230,000 | 40,513,000 | |
| Research and development | 5,895,000 | 3,026,000 | |
| Total operating expenses | 49,125,000 | 43,539,000 | |
| Loss from operations | -22,080,000 | -11,232,000 | |
| Interest expense, net | -5,497,000 | -6,548,000 | |
| Income tax expense | -25,000 | ||
| Net loss | -27,602,000 | -17,780,000 | |
| Net loss per share: | Basic | -0.74 | -0.5 |
| Net loss per share: | Diluted | -0.74 | -0.5 |
Income Statement
For the Three Months Ended March 31, — Selected financial highlights regarding Non-GAAP operating results for the three months March 31, 2026 and 2025 are as follows:
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Total revenues | 44,203,000 | 47,831,000 | |
| Gross margin | 61.0% | 68.0% | |
| Net loss | -27,602,000 | -17,780,000 | |
| Adjusted EBITDA(1) | -12,659,000 | -1,985,000 | |
| Net loss per share: | Basic | -0.74 | -0.5 |
| Net loss per share: | Diluted | -0.74 | -0.5 |
Income Statement
For the Three Months Ended March 31,
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | |
|---|---|---|
| GAAP net loss | -27,602,000 | -17,780,000 |
| Stock-based compensation and expenses | 3,837,000 | 4,556,000 |
| Interest expense, net | 5,497,000 | 6,548,000 |
| Income tax expense | 25,000 | |
| Depreciation | 455,000 | 465,000 |
| Amortization of intangible assets | 5,129,000 | 4,226,000 |
| Adjusted EBITDA | -12,659,000 | -1,985,000 |
Income Statement
For the Three Months Ended March 31, — First Quarter 2026 Financial Results:
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | |
|---|---|---|
| Total revenues | 44,203,000 | 47,831,000 |
| Gross margin | 61.0% | 68.0% |
| Net loss | -27,602,000 | -17,780,000 |
| Adjusted EBITDA(1) | -12,659,000 | -1,985,000 |
| Net loss per share, basic and diluted | -0.74 | -0.5 |
Income Statement
For the Three Months Ended March 31, — UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Total revenues | 44,203,000 | 47,831,000 | |
| Cost of sales | -17,158,000 | -15,524,000 | |
| Gross profit | 27,045,000 | 32,307,000 | |
| Selling, general and administrative | 43,230,000 | 40,513,000 | |
| Research and development | 5,895,000 | 3,026,000 | |
| Total operating expenses | 49,125,000 | 43,539,000 | |
| Loss from operations | -22,080,000 | -11,232,000 | |
| Interest expense, net | -5,497,000 | -6,548,000 | |
| Income tax expense | -25,000 | ||
| Net loss | -27,602,000 | -17,780,000 | |
| Net loss per share: | Basic and diluted | -0.74 | -0.5 |
Income Statement
For the Three Months Ended March 31, — RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | |
|---|---|---|
| GAAP net loss | -27,602,000 | -17,780,000 |
| Stock-based compensation and expenses | 3,837,000 | 4,556,000 |
| Interest expense, net | 5,497,000 | 6,548,000 |
| Income tax expense | 25,000 | |
| Depreciation | 455,000 | 465,000 |
| Amortization of intangible assets | 5,129,000 | 4,226,000 |
| Adjusted EBITDA | -12,659,000 | -1,985,000 |
Balance Sheet
March 31, 2026 — CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, 2026 | December 31, 2025 | ||
|---|---|---|---|
| ASSETS | Cash and cash equivalents | 94,644,000 | 72,927,000 |
| ASSETS | All other current assets | 131,740,000 | 138,823,000 |
| ASSETS | Total current assets | 226,384,000 | 211,750,000 |
| ASSETS | All other assets | 193,159,000 | 187,732,000 |
| ASSETS | TOTAL ASSETS | 419,543,000 | 399,482,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Current liabilities | 91,439,000 | 96,302,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | Loans payable, net of unamortized debt discount | 292,087,000 | 243,184,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | All other liabilities | 7,666,000 | 7,905,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | TOTAL LIABILITIES | 391,192,000 | 347,391,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | TOTAL STOCKHOLDERS’ EQUITY | 28,351,000 | 52,091,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | 419,543,000 | 399,482,000 |
Cash Flow
For the Three Months Ended March 31, — CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Three Months Ended March 31, – 2026 | For the Three Months Ended March 31, – 2025 | ||
|---|---|---|---|
| Net cash provided by (used in): | Operating activities | -8,992,000 | 19,668,000 |
| Net cash provided by (used in): | Investing activities | -18,203,000 | -212,000 |
| Net cash provided by (used in): | Financing activities | 48,912,000 | 23,000 |
| Net cash provided by (used in): | Net change in cash and cash equivalents | 21,717,000 | 19,479,000 |
| Net cash provided by (used in): | Cash and cash equivalents at beginning of the period | 72,927,000 | 47,247,000 |
| Net cash provided by (used in): | Cash and cash equivalents at end of the period | 94,644,000 | 66,726,000 |
Full release
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward—looking statements.”
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks and uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general, including the ongoing communications with the U.S. Food and Drug Administration relating to compliance and quality plans at our outsourcing facility in New Jersey; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange
Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. Such... (truncated)of charge on the SEC’s web site at sec.gov. Undue reliance should not be placed on forward-looking-statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking-statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Contact:
Mike
Biega, VP of Investor Relations and Communications mbiega@harrowinc.com
617-913-8890
HARROW, INC.